Vanda Pharmaceuticals reported strong phase 2 results for a candidate that could be used with GLP-1 drugs. Despite potential catalysts, the target market appears small and risky. The weight loss market is hot, with leaders like Eli Lilly and Novo Nordisk. Vanda’s tradipitant aims to mitigate side effects of GLP-1 drugs.

The weight loss market is evolving, with smaller companies like Vanda Pharmaceuticals gaining attention. Vanda’s unconventional approach focuses on reducing side effects of GLP-1 medications. Their recent phase 2 results showed promise, leading to plans for a phase 3 study early next year.

Vanda Pharmaceuticals’ tradipitant posted solid phase 2 results, aiming to reduce vomiting side effects of GLP-1 drugs. Despite potential, the FDA issued a complete response letter for another condition. The market opportunity for tradipitant may be limited, impacting its growth potential.

Vanda Pharmaceuticals faces challenges despite strong phase 2 results for tradipitant. The market opportunity for the candidate appears limited, impacting potential growth. With a small market value, Vanda may face risks with regulatory approvals and market acceptance. Investors seeking growth may look elsewhere in the weight loss market.

Read more at Yahoo Finance: Should You Invest in This Under-the-Radar Weight Loss Stock?